Brief: Kazia Therapeutics To Request FDA Type C Meeting To Discuss Overall Survival Data In GBM And Potential NDA Filing In Alignment With FDA Initiative Project Frontrunner
27/10/2025 11:23
Oct 27 (Reuters) - Kazia Therapeutics Ltd KZIA.O: KAZIA THERAPEUTICS TO REQUEST FDA TYPE C MEETING TO DISCUSS OVERALL SURVIVAL DATA IN GBM AND POTENTIAL NDA FILING IN ALIGNMENT WITH FDA INITIATIVE PROJECT FRONTRUNNER KAZIA THERAPEUTICS LTD - SEEKS FDA FEEDBACK ON REGULATORY PATHWAY UNDER PROJECT FRONTRUNNER FOR PAXALISIB Source text: ID:nPn3pk4FHa Further company coverage: KZIA.O
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering